Argenx
ARGX
#627
Rank
NZ$52.42 B
Marketcap
$864.82
Share price
1.13%
Change (1 day)
-2.04%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : NZ$0.86 B

According to Argenx 's latest financial reports the company's total liabilities are NZ$0.86 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Argenx - Total liabilities on balance sheet (from 2021 to 2020)

Total liabilities by year

Year Total liabilities Change
2022-12-31NZ$0.50 B9.41%
2021-12-31NZ$0.46 B-55.15%
2020-12-31NZ$1.02 B43.82%
2019-12-31NZ$0.71 B814.52%
2018-12-31NZ$78.22 M48.58%
2017-12-31NZ$52.65 M-22.24%
2016-12-31NZ$67.71 M346.6%
2015-12-31NZ$15.16 M-4.67%
2014-12-31NZ$15.9 M106.97%
2013-12-31NZ$7.68 M-24.08%
2012-12-31NZ$10.12 M50.46%
2011-12-31NZ$6.72 M92.01%
2010-12-31NZ$3.5 M